Abstract

Blood and blood-component therapy triggers immunological reactions in recipients. Transfusion-related immunomodulation [TRIM] is an important complex biological immune reaction to transfusion culminating in immunosuppression. The mechanisms underlying TRIM include the presence of residual leukocytes and apoptotic cells, the transfusion of immunosuppressive cytokines either present in donor components or generated during blood processing, the transfer of metabolically active growth factor-loaded microparticles and extracellular vesicles and the presence of free hemoglobin or extracellular vesicle-bound hemoglobin. TRIM variables include donor-specific factors as well as processing variables. TRIM may explain, at least in part, the controversial negative clinical outcomes observed in cancer patients receiving transfusion in the context of curative-intent surgeries. The use of novel technologies including metabolomics and proteomics on stored blood may pave the way for a deeper understanding of TRIM in general and its impact on cancer progression.

Original languageEnglish
Pages (from-to)336-340
Number of pages5
JournalTransfusion and Apheresis Science
Volume56
Issue number3
DOIs
Publication statusPublished - Jun 1 2017

Fingerprint

Immunomodulation
Neoplasms
Hemoglobins
Tissue Donors
Metabolomics
Immunosuppressive Agents
Antigen-Antibody Complex
Proteomics
Immunosuppression
Intercellular Signaling Peptides and Proteins
Leukocytes
Cytokines
Technology

Keywords

  • Cancer
  • Progression
  • Transfusion-related immunomodulation
  • TRIM

ASJC Scopus subject areas

  • Hematology

Cite this

Transfusion-related immunomodulation and cancer. / Goubran, Hadi; Sheridan, David; Radosevic, Julia; Burnouf, Thierry; Seghatchian, Jerard.

In: Transfusion and Apheresis Science, Vol. 56, No. 3, 01.06.2017, p. 336-340.

Research output: Contribution to journalReview article

Goubran, H, Sheridan, D, Radosevic, J, Burnouf, T & Seghatchian, J 2017, 'Transfusion-related immunomodulation and cancer', Transfusion and Apheresis Science, vol. 56, no. 3, pp. 336-340. https://doi.org/10.1016/j.transci.2017.05.019
Goubran, Hadi ; Sheridan, David ; Radosevic, Julia ; Burnouf, Thierry ; Seghatchian, Jerard. / Transfusion-related immunomodulation and cancer. In: Transfusion and Apheresis Science. 2017 ; Vol. 56, No. 3. pp. 336-340.
@article{ff90a283b4d746bc8db34fdd54df97ba,
title = "Transfusion-related immunomodulation and cancer",
abstract = "Blood and blood-component therapy triggers immunological reactions in recipients. Transfusion-related immunomodulation [TRIM] is an important complex biological immune reaction to transfusion culminating in immunosuppression. The mechanisms underlying TRIM include the presence of residual leukocytes and apoptotic cells, the transfusion of immunosuppressive cytokines either present in donor components or generated during blood processing, the transfer of metabolically active growth factor-loaded microparticles and extracellular vesicles and the presence of free hemoglobin or extracellular vesicle-bound hemoglobin. TRIM variables include donor-specific factors as well as processing variables. TRIM may explain, at least in part, the controversial negative clinical outcomes observed in cancer patients receiving transfusion in the context of curative-intent surgeries. The use of novel technologies including metabolomics and proteomics on stored blood may pave the way for a deeper understanding of TRIM in general and its impact on cancer progression.",
keywords = "Cancer, Progression, Transfusion-related immunomodulation, TRIM",
author = "Hadi Goubran and David Sheridan and Julia Radosevic and Thierry Burnouf and Jerard Seghatchian",
year = "2017",
month = "6",
day = "1",
doi = "10.1016/j.transci.2017.05.019",
language = "English",
volume = "56",
pages = "336--340",
journal = "Transfusion and Apheresis Science",
issn = "1473-0502",
publisher = "Elsevier Limited",
number = "3",

}

TY - JOUR

T1 - Transfusion-related immunomodulation and cancer

AU - Goubran, Hadi

AU - Sheridan, David

AU - Radosevic, Julia

AU - Burnouf, Thierry

AU - Seghatchian, Jerard

PY - 2017/6/1

Y1 - 2017/6/1

N2 - Blood and blood-component therapy triggers immunological reactions in recipients. Transfusion-related immunomodulation [TRIM] is an important complex biological immune reaction to transfusion culminating in immunosuppression. The mechanisms underlying TRIM include the presence of residual leukocytes and apoptotic cells, the transfusion of immunosuppressive cytokines either present in donor components or generated during blood processing, the transfer of metabolically active growth factor-loaded microparticles and extracellular vesicles and the presence of free hemoglobin or extracellular vesicle-bound hemoglobin. TRIM variables include donor-specific factors as well as processing variables. TRIM may explain, at least in part, the controversial negative clinical outcomes observed in cancer patients receiving transfusion in the context of curative-intent surgeries. The use of novel technologies including metabolomics and proteomics on stored blood may pave the way for a deeper understanding of TRIM in general and its impact on cancer progression.

AB - Blood and blood-component therapy triggers immunological reactions in recipients. Transfusion-related immunomodulation [TRIM] is an important complex biological immune reaction to transfusion culminating in immunosuppression. The mechanisms underlying TRIM include the presence of residual leukocytes and apoptotic cells, the transfusion of immunosuppressive cytokines either present in donor components or generated during blood processing, the transfer of metabolically active growth factor-loaded microparticles and extracellular vesicles and the presence of free hemoglobin or extracellular vesicle-bound hemoglobin. TRIM variables include donor-specific factors as well as processing variables. TRIM may explain, at least in part, the controversial negative clinical outcomes observed in cancer patients receiving transfusion in the context of curative-intent surgeries. The use of novel technologies including metabolomics and proteomics on stored blood may pave the way for a deeper understanding of TRIM in general and its impact on cancer progression.

KW - Cancer

KW - Progression

KW - Transfusion-related immunomodulation

KW - TRIM

UR - http://www.scopus.com/inward/record.url?scp=85020481911&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85020481911&partnerID=8YFLogxK

U2 - 10.1016/j.transci.2017.05.019

DO - 10.1016/j.transci.2017.05.019

M3 - Review article

C2 - 28606449

AN - SCOPUS:85020481911

VL - 56

SP - 336

EP - 340

JO - Transfusion and Apheresis Science

JF - Transfusion and Apheresis Science

SN - 1473-0502

IS - 3

ER -